The UK is partnering with pharmaceutical companies to sequence and analyze DNA samples from UK Biobank participants.
The project is funded with £50 million from the UK government, £50 million from the Wellcome Trust, and £100 million from four pharmaceutical firms.
23andMe and GlaxoSmithKline's partnership has uncovered half a dozen drug targets but also raised ethical questions, the Wall Street Journal reports.
SpeeDx said it will work with GlaxoSmithKline on tests to support its antibiotic clinical trials, as well as its new product development efforts.
During the five-year collaboration, the partners will research disease-causing gene mutations and develop new CRISPR-based technologies for drug discovery.
The firm is seeking approval of myChoice HRD as a test that can identify ovarian, fallopian, or peritoneal cancer patients deficient in homologous recombination DNA repair.
The project dovetails with a separate effort to sequence the whole exomes of the samples, the first 50,000 of which became available to researchers this month.
This week's news includes Illumina, Becton Dickinson, PerkinElmer, iGene Laboratory, Novacyt, Twist Bioscience, Lustgarten Foundation, and GlaxoSmithKline.
With a $300 million investment in 23andMe, GSK pivots toward personalized medicine again, while the consumer genomics firm hitches its drug development ambitions to GSK.
Pharmaceutical company GlaxoSmithKline and direct-to-consumer genetic testing company 23andMe have formed a drug discovery collaboration deal.
A South African university has told the Wellcome Sanger Institute to return DNA samples it has from indigenous African communities, The Times reports.
The University of California, Berkeley's Rasmus Nielsen and Xinzhu Wei have retracted their CCR5 gene paper due to a technical artifact.
University of Virginia researchers are exploring a genetic risk test to gauge type 1 diabetes risk, NPR reports.
In PNAS this week: researchers compare two high-grade neuroendocrine lung cancers, height among ancient Europeans, and more.